key: cord-0906308-gb51v0y7
authors: Søgaard, Ole Schmeltz; Reekie, Joanne; Johansen, Isik Somuncu; Nielsen, Henrik; Benfield, Thomas; Wiese, Lothar; Stærke, Nina Breinholt; Iversen, Kasper; Fogh, Kamille; Bodilsen, Jacob; Iversen, Mette; Knudsen, Lene Surland; Klastrup, Vibeke; Larsen, Fredrikke Dam; Andersen, Sidsel Dahl; Hvidt, Astrid Korning; Andreasen, Signe Rode; Madsen, Lone Wulff; Lindvig, Susan Olaf; Øvrehus, Anne; Ostrowski, Sisse Rye; Abildgaard, Christiane; Matthews, Charlotte; Jensen, Tomas O.; Raben, Dorthe; Erikstrup, Christian; Fischer, Thea K.; Tolstrup, Martin; Østergaard, Lars; Lundgren, Jens
title: Characteristics Associated with Serological Covid-19 Vaccine Response and Durability in an Older Population with Significant Comorbidity: The Danish Nationwide ENFORCE Study
date: 2022-03-11
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2022.03.003
sha: ef1a8ba0857082bd52077941541832cac688b6d2
doc_id: 906308
cord_uid: gb51v0y7

OBJECTIVES: To identify individual characteristics associated with serological COVID-19 vaccine responsiveness and durability of vaccine-induced antibodies. METHODS: Adults without history of SARS-CoV-2 infection from the Danish population scheduled for SARS-CoV-2 vaccination were enrolled in this parallel group, phase IV study. SARS-CoV-2 Spike IgG and Spike-ACE2-receptor-blocking antibodies were measured at days 0, 21, 90 and 180. Vaccine responsiveness was categorized according to Spike IgG and Spike-ACE2-receptor-blocking levels at day 90 post-1(st) vaccination. Non-durable vaccine-response was defined as day 90 responders that no longer had significant responses by day 180. RESULTS: Of 6544 participants completing two vaccine doses (median age 64, interquartile range:54–75), 3654 (55.8%) received BTN162b2, 2472 (37.8%) mRNA-1273, and 418 (6.4%) ChAdOx1 followed by a mRNA vaccine. Levels of both types of antibodies increased from baseline to day 90 and then decreased to day 180. The decrease was more pronounced for levels of Spike-ACE2-receptor-blocking antibodies than for Spike IgG. Proportions with vaccine hypo-responsiveness and lack of durable response were 5.0% and 12.1% for Spike IgG; 12.7% and 39.6% for Spike-ACE2-receptor-blocking antibody levels, respectively. Male sex, vaccine type and number of co-morbidities were associated with all four outcomes. Additionally, age >=75y was associated with hypo-responsiveness for Spike-ACE2-receptor-blocking antibodies (adjusted odds-ratio:1.59, 95% confidence interval:1.25–2.01) but not for Spike IgG. CONCLUSIONS: Comorbidity, male sex and vaccine type were risk factors for hypo-responsiveness and non-durable response to COVID-19 vaccination. The functional activity of vaccine-induced antibodies declined with increasing age and had waned to pre-2(nd) vaccination levels for most individuals after 6 months.

Early reports on effects of COVID-19 booster vaccination against symptomatic and severe COVID-78 19 suggested dramatic drops in the risk of infection after administration of a 3 rd vaccine dose (1). Out 79 of concern of waning immunity and non-protective levels of antibodies, health authorities in many 80 countries now recommend booster vaccination to specific risk groups based on comorbidities and/or 81 age (2, 3), or in some countries to the entire adult population (4, 5). The emergence of the SARS-82

CoV-2 variant Omicron has widely stressed the national vaccine booster initiatives (6, 7). However, 83 only sparse information on predictors associated with serological COVID-19 vaccine responsiveness 84 and durability exist from clinical phase 2 and 3 trials as most individuals with significant 85 immunodeficiency were excluded from these trials (8) (9) (10) (11) . 86 87

In the present study, we prospectively performed comprehensive SARS-CoV-2 serological profiling 88 of more than 6,500 individuals enrolled in the Danish National Cohort Study of Effectiveness and 89

Safety of SARS-CoV-2/COVID-19 vaccines (ENFORCE). We used this dataset to discriminate 90 COVID-19 vaccine responders from non-responders, and to determine risk factors for vaccine hypo-91 responsiveness and for reduced durability of vaccine-induced antibodies that may increase the risk of 92 break-through infection. 93

ENFORCE is an open-label, non-randomized, parallel group, phase IV study that enrolled Danish 96 citizens prior to their first identifier:NCT04760132) . The 97 study has seven study sites across the country covering all five Danish regions. 98 99 J o u r n a l P r e -p r o o f

The study enrolled Danish citizens 18 years or older accepting a SARS-CoV-2 vaccine. Inclusion 101 criteria were 1) Written informed consent obtained before any trial related procedures are performed; 102 2) Danish citizens eligible for SARS-CoV-2 immunization. Exclusion criteria were 1) Age <18 years; 

We assessed levels of comorbidity based on hospital diagnoses within the 5 years prior to vaccination 119 obtained from the DNPR as of each person's study entry date. The Charlson Comorbidity Index (CCI) 120 score assigns a weight (1, 2, 3, or 6) to each of 19 major disease categories and is a validated measure 121 of comorbidity [11] . With the CCI score, we defined three levels of comorbidity: low (CCI=0), 122 medium (CCI=1-2) and high (CCI≥3). 123 J o u r n a l P r e -p r o o f

The 2 nd study visit occurred prior (0-7 days) to the 2 nd vaccination (usually 21 days for BTN162b2 126 and 28 days for mRNA-1273 after the 1 st vaccination), the 3 rd study visit happened 90 days (+/-14 127 days) and the 4 th visit 180 days (+/-14 days) after the 1 st vaccination. At each study visit, blood 128 samples for measuring SARS-CoV-2 serology were obtained. China) and performed at Statens Serum Institut. An ACE2 competition assay was used to evaluate 136 the functional potential of serum antibodies for blocking SARS-CoV-2 Spike-and RBD-binding to 137 the ACE2 receptor using the ACE2 competition assay (Meso Scale Diagnostics). Results obtained by 138 the ACE2 competition assay closely correlate with results obtained in pseudovirus neutralization 139 assays (13). 140 141

Baseline data were tabulated according to vaccine type and percentages or means with interquartile 143 range (IQR) and p-values calculated with chi-squared test. Serology data are presented as geometric 144 mean titers (GMT) with 95% confidence intervals (CI). Three levels of vaccine response were defined 145 based on the participants change in Spike-IgG at day 90 relative to their pre-vaccine (baseline) levels: 146 vaccine hypo-responders were defined as individuals who had less <2 log10 increase in Spike-IgG, 147 J o u r n a l P r e -p r o o f moderate responders were individuals who had 2−3 log10 increase, and high responders as individuals 148 who had >3 log10 increase in Spike-IgG. Corresponding categories of vaccine responsiveness were 149 also made based on absolute levels of Spike-ACE-2-receptor blocking antibodies (<1, 1-4, >4 150 AU/mL) at day 90. Participant characteristics were compared across the three groups and logistic 151 regression was used to evaluate risk factors for vaccine hypo-responsiveness. Variables selected a-152 priori, included age at enrolment, sex, vaccine type, CCI score, and individual comorbidities, and 153

were evaluated in univariable and multivariable analysis. Finally, the durability of COVID-19 vaccine 154 responses was evaluated by comparing vaccine-induced antibodies at day 180 to the levels observed 155 at previous visits. 156

A total of 6544 individuals who were Spike-Ig negative and had no prior positive SARS-CoV-2 PCR 159 at baseline were included. Of these, 3654 (55.8%) received BTN162b2, 2472 (37.8%) mRNA-1273, 160 and 418 (6.4%) one dose of ChAdOx1 followed by a second dose of one of the mRNA vaccines. 161

Baseline demographics of the study participants are shown in Table 1 . The median age was 64 years 162 and 3683 (56.3%) were female. BTN162b2 vaccinees were generally older, had more comorbidity, 163 and were more likely to be categorized as high-risk individuals in the Danish vaccination program 164 than the two other groups. In contrast, the ChAdOx1/mRNA group mainly consisted of younger 165 individuals with a large representation of female health-care workers. 166 167

Of the 6544 participants, 6036 (92%) had complete SARS-CoV-2 serology measurements available 169 for the study visit prior to the second planned vaccine dose (day 21); 5662 (86.5%) and 4096 170 (62.6%) had complete SARS-CoV-2 serology at the study visits 90 and 180 days , respectively. 171

The GMT of Spike-IgG increased from 82 (95% CI: 102−110) at baseline, to 23,572 (95% CI: 174 22,503−24,692) pre-2 nd vaccination and to 167, 137 (95% CI: 161, 114) at day 90, and then 175 decreased at day 180 (61,904; 95% CI:59,225−64,704)( Figure 1A and Table S1 ). Similar patterns 176

were seen in GMT for RBD-specific IgG levels ( Figure S1 and Table S1 ). Stratifying participants 177 according to age and CCI score showed that post-vaccinations levels of Spike-IgG was progressively 178 lower with increasing age and number of comorbidities ( Figure 1B ). Similar associations with age 179 and comorbidity were also observed for RBD-IgG ( Figure S2 ). Total Spike Ig was detected in 0% at 180 baseline, and increased to 82.3% after the 1 st vaccination and 97.8% at day 90 within the cohort 181 ( Figure S3 , Table S2 ). 182 183

The median serum concentration of Spike-ACE2-receptor blocking antibodies was zero at baseline, 185

increased slightly prior to the second dose (median 1 arbitrary units[AU]/mL, IQR:1-1), and then 186 increased substantially at day 90 (median 5 AU/mL, IQR: 5-6; Figure 1C and Table S3 ). Median 187 levels at day 90 differed depending on vaccine type, and was 3 AU/mL (IQR: 3-3) for BTN162b2 188 vaccinated, 13 AU/mL (IQR: 12-13) for mRNA-1273 vaccinated, and 31 (IQR: 22-44) for those that 189 received first a single ChAdOx1 dose and then either mRNA-vaccine as their second dose. Of note, 190 this latter group received their second dose closed to the day 90 visit than the two first groups. At day 191 180, levels of Spike-ACE2-receptor blocking antibodies had decreased significantly (median 2, IQR: 192 2-2). Stratifying participants according to age and CCI score revealed that post-vaccination, antibody 193 levels were gradually lower with increasing age and number of comorbidities ( Figure 1D ). Among 194 participants with comorbidity or age >75 years, levels of Spike-ACE2-receptor blocking antibodies 195 had declined to pre-2 nd vaccination levels at day 180 (Table S3) . Similar associations with vaccine 196 type, age and comorbidity were also observed for RBD-ACE2-receptor neutralizing antibodies 197

We first categorized participants who had complete serology measurements from baseline to day 90 201 post-1 st vaccination according to the relative increase in Spike-IgG antibodies and Spike ACE-2-202 receptor-blocking antibodies from baseline. Vaccine hypo-responsiveness defined as having <2-fold 203 log10 increase in Spike IgG or Spike-ACE2-receptor blocking antibodies <1 AU/mL at day 90 was 204 seen in 5.0% and 12.7% of the cohort, respectively ( Table 2 ). The corresponding proportion of 205 individuals with vaccine hypo-responsiveness at day 180 was 12.1% for Spike IgG and 39.6% for 206

Spike-ACE2-receptor-blocking antibodies. Thereafter, and to evaluate the durability of the vaccine 207 response, among those defined as responders at day 90 and with follow-up at day 180 (n=3,474), we 208 assessed how many became hypo-responsive at day 180. According to Spike-IgG and ACE2-receptor 209 blocking antibodies, 12.1% and 28% were hyporesponsive at day 180, whereas 45% and 48% had a 210 moderate, and 43% and 24% had a strong response, respectively. 211 212

Responsiveness differed by several vaccine, demographics and co-morbidity factors (Table 2) . 214 Independent risk factors for vaccine Spike-IgG and Spike-ACE2-receptor-blocking antibody hypo-215 responders vs. moderate and high-responders were first evaluated in multivariable logistic regression 216 models including sex, age group, CCI score category, vaccine type excluding ChAdOx1 vaccinees 217 due to low numbers (Figure 2A and 2B) . For both antibodies, hypo-responsiveness was associated 218

with male sex, increasing number of comorbidities and vaccine type. Conversely, whereas older age 219 was associated with elevated risk of being hypo-responsive, as determined by low levels of Spike-220 ACE2-receptor-blocking antibodies, this was not observed with assessing Spike IgG. 221

The association with number of co-morbidities was further assessed by assessing each of the types of 223 co-morbidities ( Figure S5 ). Hypo-responders were consistently more often found among transplant 224 recipients, and patients with renal disease and malignancies. Patients with diabetes and autoimmune 225 disease had an increase chance of being hypo-responsive when assessing response by change of 226

Spike-ACE2-receptor antibody only, whereas patients with liver disease had elevated chance when 227 assessing Spike-IgG antibodies only. 228 229

Among initial responders at day 90, independent risk factors for vaccine hyporesponsiveness at day 231 180 are presented in Figure 3A (for Spike IgG) and 3B (for Spike-ACE2-receptor antibody). For both 232 antibodies assessed, risk factors for this outcome were male sex and vaccine type (mRNA-1273 233 compared to BTN162b2 aOR=0.16, 95% CI:0.09−0.27), but not age. Multiple co-morbidities were 234 associated with excess risk of hypo-responsiveness for Spike-ACE2-receptor antibody but not clearly 235 so for Spike IgG (Table S6) . 236

The present study adds significant insight into the potential causes of the observed reduction in 239 vaccine effectiveness over time across different populations (3, 14, 15) . First, we document that in 240 this large cohort of mainly middle-aged and older individuals with a substantial burden of 241 comorbidities, initial peak antibody responses to all vaccine regimens were robust in 95% of 242 vaccinated individuals. Increasing age was associated with lower levels of neutralizing antibodies, 243 but interestingly, this association was not present when we analyzed relative increases in quantitative 244 SARS-CoV-2 IgG levels. Others have also reported an association between age and neutralizing 245 antibody titers post BTN-162b2 vaccination (16). Elderly individuals are known to have reduced 246 ability to mount robust and sustained responses to new antigens and age-related decrease in the 247 production of new B cells from their precursors, may lead to production of antibodies with lower 248 avidity and affinity (17) The efficacy of the two mRNA vaccines BNT162b2 and mRNA-1273 against COVID-19 was almost 252 identical in the respective phase 3 trials but subsequent studies have indicated that total antibody 253 levels and neutralization activity may be higher after two doses of mRNA-1273 compared to 254

BNT162b2. In one report, recipients of the BNT162b2 vaccine had a 27% higher risk of documented 255 SARS-CoV-2 infection and a 70% higher risk of hospitalization for COVID-19 than recipients of the 256 mRNA-1273 vaccine over 24 weeks of follow-up in a period marked by alpha-variant predominance 257 (14). The authors also reported a trend towards higher risk of documented infection among 258

BNT162b2 vaccinees than among mRNA-1273 vaccinees over 12 weeks of follow-up in a period 259 marked by delta-variant predominance (14). Others have reported higher SARS-CoV-2-binding 260 antibody response following mRNA-1273 vaccination compared to BNT162b2 vaccination (18, 19) . 261

In contrast to our study, these two studies did not measure functional or neutralizing antibodies. 262

Indeed, we not only observed higher levels of total Spike and RBD IgG but also higher levels of such as the lipid composition of the nanoparticles used for packaging the mRNA content (8, 9, 20) . 269

Our study also had some limitations. Due to the temporal variations in the availability of specific 271 COVID-19 vaccines in Denmark, most of the individuals who were categorized as high risk in the 272 national vaccination program, received BTN162b2. This may bias the antibody responses in the 273

BTN162b2 to be lower compared to the other groups. Also, ChAdOx1/mRNA group mainly 274 consisted of female healthcare workers and the timing of their second vaccine was closer to the 3 and 275 6-month visit. We have used different strategies to balance out the inherent differences between 276 vaccine groups such as stratification and multivariate adjustment in the analyses but some residual 277 confounding may still persist and therefore, direct comparison of vaccine responses between the 278 groups should be made with caution. While we report on plasma levels of SARS-CoV-2 Spike and 279 RBD antibodies which have been shown to correlate with protection against COVID-19, data on 280 cellular immunity was not available for this study. It should be noted that T cell responses may be of 281 particular importance in preventing severe COVID-19 among those who become infected with 282 SARS-CoV-2 (13, 21). Of note, there is no universal definition of vaccine hyporesponsiveness for 283 COVID-19 vaccines. In the present study, we defined hypo-responsiveness as a 2-fold or smaller 284 increase in vaccine-induced antibodies similar to the threshold that has been applied in the 285 pneumococcal vaccine literature (22). Finally, it was beyond the scope of this study to analyze 286 association between adverse events and vaccine responsiveness but this would be of interest in future 287

In conclusion, most individuals even those at high risk mounted robust immune responses to the two 290 dose-vaccine regimens. However, certain comorbidities were strongly associated with hypo-291 responsiveness to COVID-19 vaccination. In addition, male sex and vaccine type were associated 292 with decreased durability of vaccine-induced antibodies. On a population level, the functional activity 293 of vaccine-induced antibodies appeared to wane quickly during the 6 months of follow-up 294 demonstrating that booster vaccination is required to maintain high levels of protective antibodies. 

367 Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health 368 system in the USA: a retrospective cohort study

Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine Immune Serum Samples. 371 JAMA

B-cell responses to vaccination at the extremes of age

Comparison of SARS-CoV-2 375

Antibody Response Following Vaccination With BNT162b2 and mRNA-1273

Comparison of SARS-CoV-2 Antibody Response by Age Among Recipients of the BNT162b2 vs the 379 mRNA-1273 Vaccine

381 mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability

Immunological memory 384 to SARS-CoV-2 assessed for up to 8 months after infection

Improving the 386 immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 387 9 agonist adjuvant: a randomized, controlled trial